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ABSTRACT 
 
Equine laminitis, a disease affecting the laminar tissue in the hoof, is a common and 
debilitating disease in horses with a significant impact on the equine industry. Currently 
nearly all laminitis studies are conducted in live horses, a process that is both expensive and 
limited in biological replicates. Thus the development of an in vitro model for the disease is 
an important step in advancing laminitis research. Recent evidence suggests that 
apolipoprotein A-IV (apoA-IV) may be involved in the chronic form of the disease but little 
is known about this protein in the horse, and its effects on the laminar tissue are unknown. 
The primary goal of this project was to produce a model for inducing inflammation in slices 
of laminar tissue in culture. We tested two inflammatory agents: interleukin 6 (IL-6) and 
lipopolysaccharide (LPS) and measured their effect on the expression of inflammatory 
cytokines and seven laminitis-associated genes found to be differentially expressed in horses 
with induced laminitis. The second goal of the project was to test the effects of apoA-IV on 
laminar tissue inflammation in our model in the presence and absence of the two 
inflammatory agents, and to further characterize the protein in horses by determining its 
sequence and expression pattern in this animal. 
The laminar tissue remained alive and contamination-free over the course of the 
experiment, showing the viability of our culture. IL-6 did not induce changes in gene 
expression consistent with those found in horses with laminitis. However, the addition of 
LPS led to changes in cytokine expression mimicking those seen in horses with induced 
laminitis and increased two of the seven laminitis-associated genes. The addition of apoA-IV 
had no effect on laminar tissue inflammation by itself or in the presence of IL-6 or LPS. We 
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found the highest expression of APOA4 in the liver followed by the small intestine, a pattern 
unique in its high hepatic contribution. A better understanding of how apoA-IV is produced 
and functions in horses may shed light on its role in laminitis. In the future our tissue culture 
model could be used in testing agents suspected of causing laminar tissue inflammation and 
eventually in the development and testing of potential treatments for laminitis. 
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NOMENCLATURE 
 
ACTG Gamma actin 
ADAMTS1 A disintegrin and metalloproteinase with thrombospondin motifs 1 
ApoA-IV Apolipoprotein A-IV (protein) 
APOA4 Apolipoprotein A-IV (gene) 
BSA Bovine serum albumin 
CCL2 Chemokine (C-C motif) ligand 2 
CD14 Cluster of differentiation 14 
CXCL14 Chemokine (C-X-C motif) ligand 14 
DEFB4 Beta-defensin 2 
IFN-γ Interferon gamma 
IL-1β Interleukin-1β 
IL-6 Interleukin-6 
IL-8 Interleukin-8 
LBP Lipopolysaccharide binding protein 
LPS Lipopolysaccharide 
MMP matrix metalloproteinase 
SOD2 Superoxide dismutase 2, mitochondrial  
S100A8 S100 calcium binding protein 8 
TLR4 Toll-like receptor 4 
TNF-α Tumor necrosis factor alpha 
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1. INTRODUCTION 
 
1.1 Pathology and impact of laminitis  
Laminitis is a common equine disease, having troubled horse owners for centuries 
with mention in literature dating back to ancient Greece [1]. The disease is widespread and 
devastating, frequently resulting in permanent lameness or euthanasia. It develops when the 
laminar tissue (Figure 1.1), a complex structure of overlapping epidermal and dermal laminae 
connecting the hoof wall and third phalanx, becomes inflamed. This inflammation can be 
precipitated by a variety of factors discussed later. In the acute stage of the disease, laminitis 
can be recognized by a bounding digital pulse at the fetlock and abnormally high hoof 
temperature [2]. Subsequent damage to the laminar tissue can lead to displacement of the 
third phalanx and transition into the chronic form of the disease. This acute to chronic 
transition is very common with up to 75 % of horses affected by acute laminitis developing 
chronic laminitis [3]. Given the frequency of occurrence of the disease and likelihood of 
long-term medical treatment or euthanasia, its economic impact is substantial. One USDA 
study found 13 % of equine farms surveyed were impacted by laminitis and 2.1 % of 
included horses were affected at some point in the one year period in which the study took 
place [4]. Another study estimated that 15 % of horses develop laminitis at some point in 
their lives, and that $13 million is lost annually in association with the disease due to 
mortality and medical expenses [3]. The pervasiveness and typically poor outcome associated 
with the disease make laminitis an important subject for further study. The condition is not 
restricted to domestic animals; a recent study found chronic laminitis affecting between 40 
and 93 % of individuals sampled from five wild herds of Australian feral horses [5]. Despite 
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the prevalence and long reported history of the disease, owners of affected animals are left 
with few prevention and treatment options, particularly because the underlying causes of 
laminitis are not well understood. While there remains significant debate over what specific 
mechanisms lead to the development of laminitis (potential reasons outlined below), 
evidence has emerged pointing to a systemic inflammatory response in horses that develop 
the disease [6-8].  
 
 
Figure 1.1 – Laminar tissue morphology. Left: a slice of laminar tissue stained with 
hematoxylin-eosin showing the primary dermal lamellae (PDL), secondary dermal lamellae 
(SDL), primary epidermal lamellae (PEL), and secondary epidermal lamellae (SEL) [9]. 
Middle: cross-section of the hoof showing the orientation of (A) the third phalanx, (B) the 
laminar tissue, and (C) the hoof wall. Right: rotation of the distal phalanx (DP) from its 
original position along the dotted yellow line and formation of the lamellar wedge (solid 
yellow line) in a horse with chronic laminitis [10]. 
 
 
A wide range of events can trigger the development of laminitis. Perhaps the best 
known of these is carbohydrate overload in which a horse develops laminitis subsequent to 
ingesting large quantities of carbohydrate rich food such as when a horse is given access to a 
lush pasture or abnormally large quantity of grain [4, 11, 12]. Laminitis has also been 
associated with trauma to the foot [13, 14], sepsis [15, 16], and metabolic syndrome [8, 17, 
18]. While a variety of events precipitating laminitis have been identified, the mechanisms by 
which laminar tissue inflammation is initiated remains unknown. Changes in hindgut 
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microbiota have been implicated in the development of laminitis in a number of studies [19-
22]. During oligofructose overload induced laminitis the population of bacteria has been 
shown to shift from primarily gram-negative to primarily gram-positive strains, and an 
increase in streptococcal species has been reported [19-21]. In the carbohydrate model 
streptococcal species were shown to decrease at 8 hours when compared with controls but to 
be similar to control values by 24 hours, and anaerobic streptococcal species were decreased 
at both time points [20]. It has been suggested that endotoxemia resulting from a shift in 
hindgut bacterial communities is responsible for inducing laminitis, although administration 
of lipopolysaccharide (LPS) does not itself induce laminitis [23]. Increases in both plasma 
LPS concentration [24] and serum immunoglobulin titers against core LPS [25] have been 
observed to increase in response to oligofructose induced laminitis and colic-causing 
gastrointestinal disorders, respectively. It has also been suggested that vasoactive amines 
may act to induce laminitis by causing ischemia and oxidative damage [26-28] and that 
matrix metalloproteinases (MMPs) [29, 30] and lactic acidosis resulting from bacterial shifts 
in the gut [31, 32] may be responsible for the degradation of the laminar tissue.  There is also 
a metabolic component to laminitis, and horses with metabolic syndrome are predisposed to 
developing laminitis [8, 17, 18]. The mechanisms behind this endocrinopathic associated 
laminitis are not well understood, but it is thought that insulin resistance plays a role, and 
laminitis has been induced in live animals subjected to hyperinsulinemia [33, 34].  
Although there are differences in the progression of laminitis brought on by the 
various causes of the disease, the basic course of the disease follows a common path. 
Laminitis can be characterized as acute in the initial 72 hours before permanent physiological 
changes to the foot have taken place, or chronic, after separation of the distal phalanx from 
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the hoof wall has occurred. The acute stage of laminitis is characterized by a bounding digital 
pulse, increased temperature in the hoof, and the onset of lameness. Lameness is often scaled 
according to the internationally accepted Obel Scoring System of 1-4 [35]. In the Obel 
Scoring System clinical signs range from Grade 1, with the horse frequently shifting weight 
and having a shortened stride at the trot, to Grade 4, with the horse exhibiting extreme 
reluctance to move. Increased infiltration of leukocytes into the laminar tissue can be 
measured within the first 24 hours of the disease. This has been observed in three models of 
laminitis: black walnut heartwood extract [6, 36], carbohydrate overload [37], and 
oligofructose administration [38] although this change was not seen following the 
administration of LPS [36].  
Structural   changes in the hoof also play an important role in the pathology of 
laminitis. The laminar tissue is an intricate structure, composed of overlapping dermal and 
epidermal laminae that supports the load-bearing distal phalanx within the hoof (Figure 1.1). 
The primary epidermal laminae (PEL) are an extension of the keratin-based hoof wall 
towards the interior of the hoof comprised of keratinocytes. The PEL attach to the secondary 
epithelial laminae (SEL), which are composed of a basal cells and extend in the direction of 
the distal phalanx [39]. The SEL are attached to the secondary dermal laminae (SDL) by the 
basement membrane, the extracellular matrix forming a structural partition between the 
dermis and epidermis composed of proteins including collagen and laminin [39-42]. Unlike 
the epidermal laminae the dermal laminae include vasculature, and consist of strong 
collagen-based connective tissue that is attached to the distal phalanx [39]. During laminitis 
this delicate architecture becomes disrupted and its ability to support the distal phalanx is 
greatly impaired, often leading to failure of the laminar tissue. 
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One of the earliest structural changes to occur during acute laminitis is the 
detachment of the basement membrane. Detachment has been measured at 48 hours post 
administration of carbohydrate [43] and 12 hours post oligofructose administration [38]. As 
the disease progresses, lesions are formed in the lamellae and the architecture of the tissue is 
compromised [33, 34, 43]. Additional damage occurs in the vasculature, and increased blood 
flow has been implicated as having a role in the failure of the laminar tissue [44]. Frequently, 
damage to the laminar tissue is so severe that the coffin bone becomes detached from the 
hoof wall, at which point the disease enters its chronic phase with associated life-long 
medical problems. 
Chronic laminitis is characterized by rotation of the distal phalanx and the widening 
of the laminar region in the formation of the lamellar wedge (Figure 1.1) [10]. Studies on 
chronic laminitis have rarely been carried out, but those that have been conducted have found 
significant changes in the foot of affected individuals. Horses with chronic laminitis have 
substantial alterations in the structure of the basement membrane zone [45], the area 
separating the dermal and epidermal laminae, as well as significantly increased levels of 
bacteria isolated from the laminae when compared with controls (especially members in the 
phylum Actinobacteria and in the Staphylococcus genus) [46]. Carter et. al. [47] found that 
the regulation of epidermal stem cells is altered in horses with chronic laminitis. P63, a 
marker of proliferation potential for epidermal cells, is expressed at significantly lower levels 
in the hooves of horses with chronic laminitis and the authors propose that this change in 
expression has a causative role in the formation of the lamellar wedge. In addition to 
alterations in the basement membrane and the formation of the lamellar wedge, a neuropathic 
component has also been described in association with chronic laminitis. Expression of ATF, 
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a neuronal injury marker, and neuropeptide Y are increased in horses with chronic laminitis, 
in addition to changes in axon shape and reduction of fibers, and alteration in the myelin 
sheath in the lateral digital nerve [48]. Given that most horses who survive the acute stage of 
laminitis go on to develop chronic laminitis, further research on this stage of the disease is 
essential.  
Changes in inflammatory cytokine expression in laminar tissue have been observed in 
various models of acute laminitis. The expression of IL-6 mRNA is upregulated in the black 
walnut extract [49, 50], carbohydrate [51] and oligofructose models [38]. The expression of 
IL-1β mRNA has also been shown to increase across all three models [49-52]. A number of 
other cytokines have altered mRNA expression profiles in the laminar tissue during acute 
laminitis including increases in IL-8 in the black walnut extract, oligofructose [49], and 
carbohydrate [50] models, and IL-12 in the carbohydrate model [51]. Tumor necrosis factor 
alpha (TNF-α) is a cytokine frequently elevated in inflammatory responses but showed no 
change in either the carbohydrate overload model [51] or the black walnut extract model of 
laminitis [50]. Other cytokines have shown inconsistent expression patterns between models 
or studies. One study found IL-2 and Interferon gamma (IFN-γ) expression to be increased in 
the oligofructose but not black walnut extract model [49]. Another study found no change in 
IFN-γ in carbohydrate induced laminitis [51]. The anti-inflammatory cytokine IL-10 was 
found to decrease during the onset stage of the black walnut extract model but not in later 
stages of the disease [49] and showed no change in two additional studies using the black 
walnut extract model [50] and carbohydrate overload model [51]. Interestingly, a study 
looking at the protein expression of inflammatory cytokines in which a prolonged 
euglycaemic hyperinsulinaemic clamp was used to induce laminitis [53] found that IL-6 
    7 
protein expression was not increased in the laminar tissue but that there was an increase in 
the expression of TNF-α protein, in contrast to the previously described mRNA results for 
these cytokines. However, the study found no change in the expression of either protein when 
a prolonged glucose infusion was used as an alternate method of inducing laminitis.  
 
1.2 Experimental models for laminitis  
Previous studies on laminitis have predominantly relied on inducing the disease in 
live animals. Several disease models have been used, including carbohydrate or oligofructose 
overload and the administration of lipopolysaccharide or black walnut extract. While these 
studies have undoubtedly increased our understanding of the progression of the disease they 
are limited by several important disadvantages. The obvious drawback to this method is the 
need to euthanize often-healthy animals to complete a study, but there are also the associated 
problems of low sample numbers and high relative variability between animals. Additionally, 
all of these methods are based on inducing a systemic response with the effect of a 
subsequent inflammatory response in the laminar tissue. While this systemic model has its 
own merits, it has the disadvantage that the disease-causing bioactive compounds leading to 
inflammation in the laminar tissue may be many steps removed from the initial system insult. 
This disconnect can make it difficult to elucidate the mechanisms involved in initiating local 
laminar tissue inflammation. Thus, there is a need for a disease model that allows direct 
manipulation of the laminar tissue. In order to address this gap in experimental techniques, 
we have developed an in vitro tissue culture model for laminitis that allows the study of the 
effects of specific bioactive agents on laminar tissue inflammation. We use slices of tissue, 
which are more suitable as a model for laminitis than cell culture as the 3D architecture of 
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the laminar tissue, cell-cell contact, and extracellular matrix proteins are maintained. Tissue 
is cultured in Leibovitz’s L-15 medium to mimic the non-proliferative conditions of laminar 
tissue in vivo. Many samples can be taken from one animal, both increasing replicate number 
and allowing comparison of treatments within an animal. In this way the effects of variability 
between animals on experimental results can be reduced. Additionally, our model can make 
use of tissue from horses euthanized for reasons unrelated to research. This model has the 
potential to reduce the overall cost and the number of horses used in trials if implemented in 
future laminitis studies. 
While laminar tissue has been cultured in previous studies [38, 54], there have been 
significant shortcomings in replicating cellular processes in vivo. In one case [38], laminar 
tissue explants were large (15mm thick), which could potentially compromise cell survival in 
the center of the tissue. This study also used culture conditions that promoted cellular 
proliferation, which does not mimic non-proliferative in vivo cellular activity in the laminar 
tissue. A second study cultured thin slices (5mm x 5mm x1mm) in an assay measuring 
glucose uptake in the laminar tissue [54], also under culture conditions promoting cellular 
proliferation. An in vitro tissue culture method more accurately reflecting the cellular 
processes of the laminar tissue in vivo is an important need in laminitis research.  
 
1.3 The role of apolipoprotein A-IV in laminitis 
Despite the high frequency with which acute laminitis develops into the chronic form 
of the disease, few studies have focused on chronic laminitis and comparatively little is 
known about the initiation and progression of the disease at the molecular level. Chronic 
laminitis is associated with systemic changes in the horse, and Wagner et. al. [55] report that 
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horses with chronic laminitis have an increased response to intradermally administered 
allergens when compared with control horses but little is known about how these changes 
affect an animal’s susceptibly to laminar tissue inflammation. A recent proteomics study [56] 
measured increases in proteins involved in coagulation, and clotting processes, providing 
additional support for a systemic shift in horses with chronic laminitis. Notably, this study 
also showed a greater than two-fold increase in plasma levels of apolipoprotein A-IV (apoA-
IV) in horses with chronic laminitis when compared with controls [56]. In this study, 
differential gel electrophoresis (DIGE) was used to identify proteins with different 
concentrations in the plasma of horses with chronic laminitis than in controls. Of the 16 
proteins having different plasma concentrations between the two groups, apoA-IV is of 
particular interest due to previous research indicating a novel role for this protein in 
mitigating inflammation [57].  
Apolipoproteins are proteins that bind to lipids in the formation of lipoproteins, 
structures that allow for lipid transport in the circulatory and lymphatic systems. ApoA-IV 
was first described in 1977 in the high density lipoprotein fraction of rat serum [58] and later 
identified in the lymph of dogs and humans [59]. In humans and rats apoA-IV has a 
molecular weight of 46 kDa, and it has molecular weight of 44 to 45 kDa in dogs. In horses, 
apoA-IV has a unique size and expression profile which may be indicative of a unique 
function in this animal. Equine apoA-IV is reported to be around 30kDa [56], which is 
significantly smaller than reported in other species. Additionally, the predicted protein 
sequence from the NCBI protein sequence database [60] (reference sequence: 
XP_001502503.1) yields a predicted protein of 43.3kDa in the ExPASy tool ProtParam [61] 
indicating that the protein may be post translationally modified in horses. 
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  In rats apoA-IV is synthesized in both the liver and the intestine, while in humans 
synthesis is limited to the intestine [62, 63]. Our lab has found apoA-IV to be expressed in 
the liver, white blood cells, and laminar tissue in horses (unpublished data). Further study 
into the structure and distribution of apoA-IV in horses may shed light on its function in 
horses and help to explain its association with chronic laminitis.  
In addition to its role in lipid transport, a number of novel functions have been 
reported for apoA-IV. The protein plays a role in the short-term regulation of food intake 
[63] with hypothalamic apoA-IV levels becoming depleted during periods of food 
deprivation and increasing after feeding. ApoA-IV also increases insulin secretion in 
pancreatic islets under in vitro conditions of high glucose [64], is involved in the clearance of 
amyloid-β peptide in the brain [65], the accumulation of which is associated with 
Alzheimer’s disease, and acts as an anti-oxidant [66].  
Importantly, apoA-IV has an anti-inflammatory function in mice and is associated 
with chronic inflammatory diseases in humans. ApoA-IV knockout mice exhibit a more 
severe inflammatory response in dextran sulfate sodium induced colitis as compared to wild 
type mice, an effect that is substantially reversed through the administration of recombinant 
human apoA-IV [57]. These results demonstrate that apoA-IV has the ability to mitigate 
intestinal inflammation, and although the mechanism is not completely understood, the 
authors suggest that apoA-IV reduces leukocyte recruitment by inhibiting the expression of 
P-selectin in endothelial cells. Intriguingly, the plasma levels of ApoA-IV are increased in 
patients with rheumatoid arthritis [67] and ankylosing spondylitis [68], both conditions which 
involve chronic systemic inflammation. Although there is evidence linking increased apoA-
IV levels and chronic laminitis, and the protein has been shown to have an anti-inflammatory 
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effect in mice, the effects of the protein on laminar tissue are unknown. Thus, further 
research is warranted to determine if apoA-IV plays a role in modulating inflammation in 
laminar tissue. 
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2. JUSTIFICATION FOR UNDERTAKING THE PROJECT 
 
Equine laminitis is debilitating disease frequently occurring in horses, which has a 
significant impact on the equine industry. Laminitis is characterized by inflammation of the 
laminae, the supporting structure connecting the hoof wall to the third phalanx. The condition 
can be precipitated by a variety of factors including carbohydrate overload [4, 11, 12], 
insulin-intolerance [69], and mechanical damage [13, 14, 70]. Despite the high prevalence of 
the disease [4] and its typically poor outcome, little is known about the mechanisms driving 
laminar tissue inflammation and few treatment options are available. Currently, nearly all 
laminitis studies are conducted in live horses, a process that is both expensive and limited in 
biological replicates. A significant limitation in laminitis research today is the lack of a 
model system in which laminar tissue can be manipulated in vitro. Thus, the development of 
an in-vitro model for the disease is an important step in furthering laminitis research. To 
address this gap, in this study we characterize a model for inducing inflammation in slices of 
laminar tissue in culture. Laminar tissue was cultured in 1mm thick slices to ensure that the 
structure of overlapping dermal and epidermal laminae remains intact. Tissue was cultured in 
Leibovitz’s medium to account for the non-proliferative conditions found in vivo. We tested 
two agents for inducing inflammation: Interleukin 6 (IL-6) and lipopolysaccharide (LPS) 
over a series of time points (4, 15, 24, and 48 h). In order to assess inflammation we 
measured IL-1β, IL-6, IL-8, TNF-α, and IFN-γ, cytokines that have been measured in 
previous in vivo laminitis studies [24, 37, 38, 49-52]. We also measured the expression of 
ADAMTS1, CCL2, CD14, S100A8, DEFB4, SOD2, and CXCL14, genes that have 
previously been shown to be differentially expressed in the oligofructose and carbohydrate 
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models of induced laminitis [71]. In the future this model could be used in elucidating the 
mechanisms behind laminar tissue inflammation and eventually in the development and 
testing of potential treatments for laminitis. 
A recent study has identified several proteins that are upregulated in horses with 
chronic laminitis, notably apolipoprotein A-IV (apoA-IV) [56]. ApoA-IV has been shown to 
be correlated with chronic inflammatory diseases in humans [67, 68] and to have anti-
inflammatory functions in mitigating experimentally induced colitis in mice [57]. These 
previous findings suggest that apoA-IV may be involved in the inflammatory response of 
horses experiencing laminitis. In this study we seek to determine whether apoA-IV plays a 
role in the development of laminar tissue inflammation through the use on an in-vitro model. 
Equine apoA-IV must have a different sequence from human apoA-IV because of its 
significantly smaller size, and its expression in white blood cells and laminar tissue is unique 
from the expression profile in humans and rodents [62, 63]. Determining how the sequence 
of equine apoA-IV varies from other species and the cellular source in the horse will provide 
important information about what type of functions it performs in this species. Despite the 
correlation between increased levels of apoA-IV and laminitis it remains unknown how the 
protein affects the laminar tissue, information that is key to understanding why it is increased 
in horses with laminitis. In order to address these gaps in knowledge, we planned to isolate 
and sequence apoA-IV, determine its full expression profile in the horse, and conducted a 
series of laminar tissue culture experiments in which we measured the effects of apoA-IV on 
inflammation in laminar tissue in vitro.  
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3. OBJECTIVES AND POTENTIAL OUTCOMES 
 
The first objective of this project was to develop and characterize an in-vitro tissue 
culture model for equine laminitis. Our goal was to develop a tissue culture model for 
laminitis using 1 mm thick laminar tissue slices of laminar tissue cultured under non-
proliferative conditions. The model was optimized to ensure that cells throughout the slice 
would survive and that the model remained contamination free.  Two different agents, IL-6 
and LPS, were used to induce inflammation in the tissue and the gene expression of 
inflammatory cytokines were measured by real time PCR to assess the degree of laminar 
tissue inflammation. Furthermore, gene expression in the model was compared with gene 
expression of laminitis associated genes identified in two in-vivo models for laminitis.  
We expected that we would be able to develop a functional tissue culture technique in 
which the cells throughout the entire slice remain alive for 48 h without contamination. 
Although this method includes significant modifications to previously published techniques, 
we had already demonstrated the ability to keep laminar tissue viable over a period of at least 
4 days as assessed by of an MTT assay. Thus, we anticipated that a viable model could be 
produced from this work. We had received on average approximately one horse per month 
from the Anatomic Pathology Laboratory at the Texas A&M University College of 
Veterinary Medicine and so anticipated that we will be able to access tissue from enough 
horses to further optimize the model and perform experiments on at least 5 animals.  
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The second objective of this project was to evaluate the role of apoA-IV in laminar 
tissue inflammation. Using the above model developed in our lab, our second goal was to 
measure both the effects of apoA-IV on inflammatory markers and the effects of induced 
inflammation on apoA-IV gene and protein expression. We also attempted isolate equine 
apoA-IV to determine the protein sequence through mass spectrometry. The sequence was to 
be compared with the human apoA-IV sequence in order to identify structural differences 
and determine if the smaller equine protein is missing any regions that are likely to be 
functionally important. 
We expected that this research would result in a comprehensive profile of apoA-IV 
mRNA and protein expression in the horse given that we had already been able to measure 
APOA4 expression [72] and protein concentration [56] in our laboratory. We expected to be 
able to isolate high-purity apoA-IV for sequencing by following a protocol that has been 
successfully used previously to isolate bovine apoA-IV [73] and to find significant structural 
differences between equine apoA-IV and apoA-IV from humans because of the significant 
size difference already measured [56]. While we acknowledge that there are most likely 
multiple proteins important in the inflammatory response in laminitis, apoA-IV was an ideal 
candidate due to its known association with the disease [56] and its ability to mitigate 
inflammation [57]. We expected to measure a significant decrease in the concentration of 
inflammatory markers with the addition of apoA-IV based on the anti-inflammatory action 
previously reported for the protein [57]. Given that we have been successful in measuring 
differences in gene expression in laminar tissue culture we are confident we will be able to 
detect any differences between treatments.  
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4. MATERIALS AND METHODS 
 
4.1 Tissue collection for APOA4 expression panel 
Tissue samples were collected from 5 horses euthanized for reasons unrelated to this 
study, at the Anatomic Pathology Laboratory at the Texas A&M College of Veterinary 
Medicine. Only horses with a postmortem interval of less than 1 h were included. Samples 
from the small intestine, colon, cecum, liver, brain, stomach, tongue, pancreas, lung, heart, 
spleen, adipose tissue, and eye (Table 4.1) were collected in RNAlater ® (Qiagen, Valencia, 
CA) and stored on ice for transport to the laboratory where they were stored at 4˚C overnight, 
then frozen at -80˚ C after excess RNAlater ® was removed. As evident from Table 4.1, only 
5 tissue samples could be obtained from all animals. 
 
 
    
Tissue 
 
Horse 
 
1 2 3 4 
Adipose   x     
Brain x x x x 
Cecum x x x x 
Colon x x x x 
Eye x       
Heart x x     
Liver x x x x 
Lung x x     
Pancreas x  x      
Skeletal muscle x x     
Small intestine x x x x 
Spleen   x x   
Stomach   x x   
Tongue  x x     
 
Table 4.1 – Tissue collected from each of 5 horses. An x marks that the tissue was collected 
from that individual. 
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4.2 Laminar tissue collection and culture 
 Laminar tissue from 5 separate horses from those used in the tissue panel was 
obtained from the Anatomic Pathology Laboratory at the Texas A&M College of Veterinary 
Medicine. Only horses euthanized for reasons unrelated to lameness arising from the hoof 
with a postmortem interval of less than 1 h were used. Tissue was collected from the two 
front feet of each horse. Laminar tissue was dissected from along the sagittal plane of the 
hoof after it was transected with a band saw (Figure 4.1). Tissue was then sectioned into 5 x 
5 x 1 mm slices using a McIlwain Tissue Chopper (Mickle Laboratory Engineering Co. Ltd., 
Surrey, UK) and washed 3 times in PBS containing the fungicide amphotericin B (2.5µg/ml; 
Life Technologies, Grand Island, NY). Two fresh slices were collected and frozen at -80˚C 
(one snap frozen in liquid nitrogen for protein analysis and one first stored overnight at in 
RNAlater ® at 4˚C for RNA analysis). The remaining slices were cultured in a 48-well plate 
at 37˚C (Figure 4.1). Each slice was cultured in 300µl Leibovitz’s media with amphotericin 
B (0.5µg/ml; Life Technologies) and penicillin-streptomycin (100u/ml penicillin and 
100ug/ml streptomycin; Life Technologies). 
 
 
Figure 4.1 – Steps in tissue collection and culture preparation. 
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Tissue from each horse was subjected to the following treatments: a control sample in 
media alone, BSA (as a control for the samples containing IL-6, which required BSA as a 
carrier), LPS (an inflammatory agent), IL-6 (a second inflammatory agent), endotoxin-free 
recombinant human apoA-IV (to test the effects of the protein alone), apoA-IV and LPS (to 
test the effects of apoA-IV on the development of LPS-induced inflammation), and apoA-IV 
and IL-6 (to test the effects of apoA-IV on the development of IL-6-induced inflammation) 
(Table 4.2). Two slices from each treatment were collected at each time point (4, 15, 24, and 
48 h): one for measurement of protein concentration by western blot (snap frozen in liquid 
nitrogen) and one for measurement of gene expression (stored at 4˚C overnight in RNAlater 
® then frozen at -80˚C).  
 
 
Treatment concentrations 
 
Sources of reagents 
Control (Leibovitz’s media only) Life Technologies (Grand Island, NY) 
BSA (10µg/ml) Sigma-Aldrich, Co. (St Louis, MO) 
Recombinant human apoA-IV (25µg/ml) Novoprotein (Summit, NJ) 
Recombinant equine IL-6 (100ng/ml) R&D Systems, Inc. (Minneapolis, MN) 
LPS (1µg/ml)  Sigma-Aldrich, Co. (St. Louis, MO) 
IL-6 (5ng/ml) + apoA-IV (25µg/ml) See above 
LPS (1µg/ml) + apoA-IV (25µg/ml) See above 
 
Table 4.2 – Tissue culture treatments. 
 
 
Four additional slices were cultured in media alone to verify cell survival by staining 
with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Life 
Technologies). MTT is a light-yellow tetrazolium dye that is reduced to dark purple 
formazan by dehydrogenase enzymes in metabolically active cells, and can be used to verify 
cell survival. After the addition of MTT (0.25µg/ml) to culture wells, the plate was placed 
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back in the incubator at 37˚C for 30 min, after which qualitative visual confirmation of cell 
viability throughout the slice was conducted.  
 
4.3 RNA isolation 
Individual tissue slices were minced finely with a scalpel and homogenized with a 
hand-held pellet pestle motor in 1ml QIAzol Lysis reagent (Qiagen). RNA was isolated 
according to the manufacturer’s protocol. RNA was treated with DNase (RNase-free set, 
Qiagen), followed by a cleanup with the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. RNA concentration was determined by spectrophotometer 
(Nanodrop, Germany).  
 
4.4 Reverse transcription 
Samples were checked for genomic DNA contamination prior to reverse transcription 
by running a PCR reaction for the gamma actin gene (see Table 4.3 for primer sequences). 
The reaction included 5 ng/µl RNA, 0.025 units/µl JumpStartTM REDTaq® DNA polymerase 
(Sigma-Aldrich, Co., St Louis, MO), 200µM dNTPs (Life Technologies) and 0.6µM gamma 
actin forward and reverse primers (Sigma-Aldrich) in 1X PCR Buffer (Sigma-Aldrich). 
Reactions were run by heating samples to 95°C for 1 min followed by 31 cycles of: 94°C (30 
sec), 58°C (30 sec), 72°C (30 sec), then cooled at 72°C for 5 min before being held at 12°C. 
The PCR product was run on a 2% agarose gel containing 0.01µg/ml ethidium bromide at 
100v for 1 h and imaged using a BioDoc-It ® Imaging System (UVP, LLC, Upland, CA). 
Samples showing no DNA contamination were reverse transcribed using the Superscript 
VILO cDNA Synthesis Kit (Life Technologies) according to manufacturer instructions. 
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Thereafter, 250ng RNA was added to each reaction (the maximum amount possible for the 
least concentrated RNA samples). Reactions were run with the program: 25°C for 10 min, 
42°C for 1 h, 85°C for 5 min, and then held at 12°C. Negative controls included reactions 
wherein the reverse transcriptase had been omitted.  
 
GENE FORWARD (5’-3’) REVERSE (5’-3’) 
ACTG CAGGATGCAGAAGGAAATCA CGCAGTCCATTTAGAAGCAT 
EEF1A1 TGGAAAGAAGCTGGAAGATG CAACCGTCTGTCTCATGTCA 
APOA4 GCCCGGGCTGAGGTCAATGC AAAGCGTGTTGAGCTTCTGGGTGA 
IL-1β CCAGAGGCGGCCGGGACATAAC GGGAAGGCAGCTGGGCATTGATT 
IL-6 ACTCCTTCTTCACAAGCACCGTC AGTGGGGTGGGGAAAGCAGTAG 
IL-8 GAGTGGGCCACACTGCGAAA TGGATTTTGCCCCTCAGCTCTCTT 
TNF-α CTGGCCCAGACACTCAGATCATCT CATTTGCACGCCCACTCAGC 
IFN-γ TACCTATTACTGCCAGGCCGCG ATCCAGGAAAAGAGGCCCACCA 
ADAMTS1 AGGCTCACAATGAATTTTCG CACAGCCAGCTTTTACACACT 
CCL2 CAGAAACCAACAACTCTCAGG TATAGCAGCAGGTGACTGGAG 
CD14 CAGCTCTTTCCAGAGTCCAC AGTTCTCATCGTCCACCTCA 
CXCL14 ATCACCACCAAGAGTGTGTCC TAT GCCTGCGAGAAAGAAAG 
DEFB4 TTCCTCATTGTCTTCCTGTTG ACTTAGGGGATATGCAGAAGC 
S100A8 ACGGATCTGGAGAATGCTATC TGATGTCCAACTCTTTGAACC 
SOD2 ACTTTGGTTCCTTCGACAAAT CAGGGGAATAAGACCTGTTGT 
 
Table 4.3 – Primer sequences. Housekeeping genes (red), APOA4 (yellow), inflammatory 
cytokine genes (green) and genes up-regulated in laminar tissue across 3 models of induced 
laminitis (blue). 
 
 
4.5 Qualitative PCR measurement of APOA4 
APOA4 expression was measured using the PCR conditions described above (see 
Table 4.3 for primer sequences). Each reaction included 2µl of cDNA (corresponding to 
25ng of RNA added to the reverse transcriptase reaction). The PCR product was run on a 2% 
agarose gel containing 0.01µg/ml ethidium bromide at 100v for 1 h and imaged using a 
BioDoc-It ® Imaging System (UVP, LLC, Upland, CA). 
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4.6 Measurement of APOA4 expression in tissue panel by qRT-PCR 
RNA was isolated and reverse transcribed as described above. Gene expression was 
measured by qPCR (see Table 4.3 for primer sequences) on a LightCycler 480 machine 
(Roche Diagnostics Co., Indianapolis, IN). Reactions were run with 1µl of cDNA in 20ul of 
1x SYBR Green I Master mix (Roche Diagnostics Co.) containing 0.5µM primers. Reactions 
were first denatured at 95°C for 5 min, then cycled through: 95°C (10 sec), 58°C (5 sec), and 
72°C (10 sec) 45 times. Negative controls included reactions without the addition of template 
cDNA. Data analysis was performed using the Pfaffl method [74]. Samples were normalized 
to gamma actin and calculated as a fold change from the average across all tissues.  
 
4.7 Measurement of gene expression from tissue culture experiments by qRT-PCR 
 Gene expression of 5 inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α and IFN-γ) 
and 7 genes found to be increased during laminitis across multiple models in a previous study 
(ADAMTS1, CCL2, CD14, CXCL14, DEFB4, SOD2 and S100A8) (Table 4.4) [71], were 
measured by qRT-PCR (see Table 4.3 for primer sequences). RNA was isolated from one 
slice of tissue at each time point as described above, and reverse transcribed as described 
above with reactions including 600 ng RNA. qRT-PCR was conducted as described above 
with 30 ng cDNA per reaction. Data analysis was performed using the Pfaffl method [74] 
with gamma actin as a control gene. EEF1A1 was measured as a second control gene in the 
laminitis-associated genes, and gamma actin was chosen for use over the entire experiment 
due to its lower variability across time and treatment. The effect of treatment in the tissue 
culture assays was assessed by two-way ANOVA using Prism (GraphPad Inc., La Jolla, CA). 
A p-value less than 0.05 was considered sufficient to reject the null hypothesis. Significant 
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differences between treatments were further analyzed to determine which time points were 
affected with a post-hoc Sidak’s multiple comparisons test.  
 
Gene Protein Function 
IL1B Interleukin-1 beta Inflammatory response, apoptosis, differentiation, and cellular proliferation 
IL6 Interleukin-6 Inflammatory response, B-cell maturation 
IL8 Interleukin-8 Inflammatory response, angiogenic factor 
TNF Tumor necrosis factor alpha 
Inflammatory response, coagulation, apopoptosis, cellular 
proliferation and differentiation 
IFNG Interferon gamma Immunoregulation, macrophage activation, anti-viral and anti-tumor functions 
ADAMTS1 
A disintegrin and 
metalloproteinase with 
thrombospondin 
motifs 1 
Acts to cleave aggrecan (a proteoglycan found in cartilage), and 
is associated with inflammation and weight loss in cancer 
CCL2 Chemokine (C-C motif) ligand 2 Chemotactic signal for monocytes and basophils 
CD14 Cluster of differentiation 14 
Mediates immune response to LPS by binding its monomeric 
form and presenting it to the TLR4 complex 
CXCL14 Chemokine (C-X-C motif) ligand 14 
Inflammatory response and immunoregulation. Attracts 
neutrophils and dendritic cells. 
DEFB4 Beta-defensin 2 Inflammatory regulation and antibiotic activities 
SOD2 Superoxide dismutase 2, mitochondrial  
Transforms toxic superoxide anion radicals into hydrogen 
peroxide and diatomic oxygen 
S100A8 S100 calcium binding protein A8 
Inflammatory response and immunoregulation. Complexes with 
S100A9 to form calprotectin. Involved in neutrophil recruitment 
and scavenging oxidants to reduce tissue damage. 
 
Table 4.4 – Gene names and functions. 
 
 
4.8 Sequencing of primer product 
PCR amplification for each primer (Table 4.3) was run as described above in a 10µl 
reaction. The product was cleaned by adding 4µl ExoSap-it ® (Affymetrix, Santa Clara, CA) 
and incubated in a thermal cycler at 37°C for 15 min followed by 15 min at 80°C. A 
terminator reaction was then run using 1µl of cleaned-up PCR product, 2µl Big Dye v 1.1 
(Life Technologies), 1µl of 2µM forward primer, and 1µl of sterile water. The reaction was 
run in a thermo cycler at 96°C for 1 min followed by 25 cycles of: 96°C for 10 sec, 50°C for 
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5 sec, and 60°C for 4 min, then held at 4°C. Excess dNTPs were removed with BioMax Spin-
50 mini-columns (BioMax Inc., Arnold, MD). Columns were centrifuged at 1000 x g for 3 
min at room temperature and flow-through discarded. Terminator reaction product was then 
added to the center of each column and spun for 3 min at 1000 x g, and the purified sample 
was recovered. Samples were lyophilized in a Vacufuge ® vacuum concentrator (Eppendorf, 
Hamburg, Germany), and submitted to the DNA Technologies Core Laboratory at Texas 
A&M University for sequencing with an ABI 3130xl Genetic Analyzer (Life Technologies). 
Sequences were edited by hand using Sequencher DNA Sequence Analysis Software (Gene 
Codes Corporation, Ann Arbor, MI). The resulting sequences were run through a nucleotide 
BLAST search [75] of the Equus caballus genome, restricted to highly similar sequences.  
 
4.9 Protein isolation 
Laminar tissue slices were finely minced with a scalpel and homogenized with a 
hand-held pellet pestle motor (Kimble Chase Kontes) using plastic DNase-free/RNase-free 
pestles in 900ml lysis buffer (0.02M Tris, 0.005M NaCl, 1% Triton-X 100). Buffer contained 
1 cOmplete Mini EDTA-free Protease Inhibitor Cocktail Tablet (Roche Diagnostics Co.) per 
10ml. Samples were shaken for 2 h on an ice block at room temperature followed by 
centrifugation at 12,000 rpm for 20 min at 4˚C. Protein-containing supernatant was removed 
and stored at -80˚C. Protein concentrations were measured using a BCA protein assay kit 
(Thermo Fisher Scientific Inc.) in which 25µl sample was added to 200µl working reagent 
and absorbance at 420nm was measured on a FLUOstar OPTIMA microplate reader (BMG 
Labtech, Ortenberg, Germany). Two replicates of each sample were averaged, and 
concentrations were calculated from a BSA standard curve. 
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4.10 2D-gel electrophoresis 
2D gel electrophoresis was conducted at the Protein Chemistry Lab at Texas A&M 
University. Laminar tissue protein (70 µg) isolated as described above was added to each of 
three 13 centimeter immobilized 4-7 pH gradient IPG DryStrips (GE Healthcare, Fairfield, 
CT). Isoelectric focusing was conducted for 50,200 Vh at 50 µA. Proteins were then 
separated on three 12% polyacrylamide gel using the HoeferTM SE 600 Series Vertical 
Electrophoresis System (Fisher Scientific International Inc., Hampton, NH). Two gels were 
then transferred to a nitrocellulose membrane by electrophoresis at 30v for 1.5 h. One 
western blot was conducted using monoclonal anti-human apoA-IV antibody and a second 
was conducted using polyclonal anti-human apoA-IV antibody as described below. The third 
gel was stained for 1 h in GelCode Blue Safe Protein Stain (Thermo Fisher Scientific Inc.) 
and destained in water overnight. Spots that were stained by the western blot in the regions 
surrounding 28 kDa and 45 kDa were selected for mass spec analysis and the corresponding 
stained sections in the GelCode Blue stained gel were cut out and trypsin-digested for 
analysis at the San Antonio Proteomics Core service lab for LC-MS/MS analysis at the 
University of Texas. 
 
4.11 Mass spec protein identification 
X! Tandem (The GPM, thegpm.org) and Mascot (Matrix Science, London, UK) were 
used to analyze the samples. Identifications made by searching the NCBI database of non-
redundant proteins were validated with the use of Scaffold 4 (Proteome Software Inc., 
Portland, Oregon). 
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4.12 Immunoprecipitation 
Immunoprecipitation was conducted using the Crosslink Magnetic IP/Co-IP Kit 
(Thermo Fisher Scientific Inc.). Magnetic beads were washed 2x in coupling buffer, then 
bound to antibody in coupling buffer containing 0.05µg/µl anti-human apoA-IV (in ascites 
fluid) for 15 min at room temperature on a rotating platform. Plasma was used as a control 
for antibody in ascites fluid. Beads were washed 4x in coupling buffer, and incubated 
overnight at 4°C in undiluted plasma on a rotating platform. Beads were then washed 3x in 
wash buffer and 1x in water. IP product and antibody were eluted in 2 washes of 100µl 
elution buffer each lasting 5 min. Product from both washes was neutralized with provided 
neutralization buffer and combined. Immunoprecipitation product was precipitated by 
methanol-chloroform precipitation for detection of apoA-IV by western blot. First, 100µl 
product from the immunoprecipitation protocol was added to 400µl methanol in a 1.5ml 
Eppendorf tube. Samples were vortexed and 100µl chloroform was added followed by 
another vortex step and the addition of 300µl of water. Samples were then centrifuged at 
13,000 x rpm for 1 min at room temperature and the upper layer removed. Next, 300µl water 
was added, samples were again vortexed, then centrifuged at 13,000 x rpm for 2 min at room 
temperature. Supernatant was removed and individual pellets were air-dried and dissolved in 
NuPAGE ® sample buffer containing DTT (dithiothreitol) as a reducing agent (Life 
Technologies) to be run on a gel for western blotting. 
 
4.13 Plasma depletion 
Equine plasma was processed with the Human IgY14 Spin Column Kit (Sigma-
Aldrich, Co.) according to manufacturer instructions to deplete the top 14 most abundant 
    26 
plasma proteins. IgY14 Spin Column was washed 2X with Dilution Buffer.  Plasma was 
diluted (15µl into 485µl Dilution Buffer) and filtered through a Corning ® Costar ® Spin-X 
filter (Sigma-Aldrich) for 1 min at 10,000 x g. Filtered plasma was applied to the column and 
mixed for 15 min, then spun 30 sec at 2,000 rpm and flow-through collected. The column 
was then washed 3 times with 500µl Dilution Buffer Column and flow-through was saved 
and pooled with the first flow-through. The column was stripped 3 times for 5 min with 
Stripping Buffer and spun 30 sec at 2,000 rpm after each round, discarding flow through. The 
column was then neutralized with Neutralization Buffer for 5 min at room temperature, then 
spun for 30 sec at 2,000 rpm, and washed three times with Dilution buffer. Pooled flow-
through was concentrated in an Amicon Ultra-15 10,000 NMWL Centrifugal Filter Unit 
(Millipore, Billerica, MA) to around 500µl. The concentrated flow-through was then re-
applied to the column and the depletion steps repeated a second time.  
 
4.14 Measurement of apoA-IV protein expression by western blot 
Samples were prepared in NuPAGE ® sample buffer containing 50mM DTT as a 
reducing agent when run under reducing conditions (Life Technologies) and heated for 10 
min at 70°C. When non-reducing conditions were used samples were prepared in NuPAGE 
® sample buffer (Life Technologies) without reducing agent or heating step. Samples were 
run on pre-poured NuPAGE® Novex® 4-12% bis-tris polyacrylamide gels in NuPAGE® 
MOPS SDS running buffer (Life Technologies) for 45 min at 180v, and then transferred to 
nitrocellulose membrane for 90 min at 30v in NuPAGE® Transfer Buffer using the XCell 
SureLockTM Mini-Cell Electrophoresis System (Life Technologies). To measure apoA-IV, 
the membrane was blocked with 5% milk in TBST (0.15M NaCl, 0.01M Tris, 0.1% Tween-
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20) for 1 h at room temperature, incubated with monoclonal anti-human apoA-IV antibody 
(Abcam, Cambridge, UK) diluted 1:1000 in 5% milk overnight at 4˚C, washed 3x10 min, 
incubated with affinity purified polyclonal HRP-conjugated goat anti-mouse IgG diluted 
1:5000 (Abcam) in 5% milk, and washed 3x15 min. Bands were visualized using the Immun-
StarTM WesternCTM chemiluminescence kit (Bio-Rad Laboratories, Hercules, CA) according 
to manufacturer instructions. For western blots with HRP-conjugated VeriBlot anti-mouse 
antibody (Abcam) monoclonal anti-human apoA-IV was used as a primary antibody at a 
dilution of 1:1000 and HRP-conjugated VeriBlot anti-mouse antibody was used as a 
secondary antibody at a dilution of 1:1000. When testing HRP-conjugated goat anti-rabbit 
antibody (Abcam), a western blot was conducted as described above without a primary 
antibody (incubated overnight in 5% milk in TBST alone) and HRP-conjugated goat-anti 
rabbit as a secondary antibody at a concentration of 1:5000. A western blot with HRP-
conjugated apoA-IV antibody (see below) was conducted as described above with HRP-
conjugated antibody at 1:160. Following the first three washes after an overnight incubation 
in the antibody, an additional 15-min wash step was added, and the membrane was 
immediately visualized.  
 
4.15 HRP-conjugation of apoA-IV antibody 
Monoclonal anti-human apoA-IV (Abcam) was conjugated to HRP using the 
EasyLink HRP Conjugation Kit (Abcam). First, 5µl EL-modifier was added to 6µl antibody 
diluted into 45µl PBS and incubated for 3 h in the dark at room temperature. Then 5µl EL-
Quencher reagent was added, and the HRP-conjugated antibody solution was stored in the 
dark at 4°C. 
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5. RESULTS 
 
5.1 Tissue culture 
Tissue culture viability: Tissue remained viable for the duration of the experiment as 
determined by staining with MTT. Two of 140 samples were contaminated as assessed by 
microscopic examination and were discarded. Several inflammatory cytokines and laminitis-
associated genes were affected by the tissue culture alone, showing differences over time in 
the control and BSA control when compared back to the fresh tissue as assessed by ANOVA. 
Of the inflammatory cytokines (Figure 5.1), IL-1β varied significantly over the course of the 
experiment in both the control and BSA control treatments, and IL-8 varied significantly over 
time in the control treatment only. IL-6, TNF-α, and IFN-γ did not change over time in either 
treatment. Of the laminitis-associated genes (Figure 5.2), CXCL14 expression changed 
significantly over time in both the control and BSA control treatments while ADAMTS1 and 
DEFB4 expression were changed only in the BSA control treatment. SOD2 and S100A8 
expression was altered significantly over the course of the experiment, but no specific 
differences between time points were identified by post hoc testing in either the control or 
BSA control treatment. The BSA control treatment was not significantly different from the 
control treatment for expression of any of the genes measured at any time point. 
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Figure 5.1 – Effects of culture over time on inflammatory cytokine gene expression for 
control and BSA control treatments compared back to fresh tissue. Significant differences (p 
< 0.05) are shown by non-overlapping uppercase (control) or lowercase (BSA control) 
letters. Data are presented as means ± SEM. 
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Figure 5.2 – Effects of culture over time on laminitis-associated gene expression for control 
and BSA control treatments compared back to fresh tissue. Significant differences (p < 0.05) 
are shown by non-overlapping uppercase (control) or lowercase (BSA control) letters. Data 
are presented as means ± SEM. 
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Primer product sequencing: All primers were validated through sequencing of amplified 
products to amplify the correct gene. 
 
IL-6: IL-6 had no significant effect on the expression of any of the five inflammatory 
cytokines (IL-1β, IL-6, IL-8, TNF-α and IFN-γ) as assessed by ANOVA at any of the time 
points measured or over the course of the experiment as a whole when compared to the 
vehicle control (Figure 5.3). IL-6 also had no significant effect on any of the seven laminitis-
associated genes (ADAMTS1, CCL2, CD14, CXCL14, DEFB4, S100A8 and SOD2) at any 
of the time points measured or over the course of the experiment as a whole when compared 
to the vehicle control (Figure 5.4). 
 
LPS: LPS significantly increased the expression of IL-1β (p < 0.001), IL-6 (p < 0.001), and 
IL-8 (p < 0.0001) at 4 h as assessed by post hoc testing but did not significantly affect the 
expression of TNF-α or IFN-γ at any of the individual time points or over the course of the 
experiment as a whole relative to the control (Figure 5.5). LPS significantly increased the 
expression of CCL2 and SOD2 (Figure 5.6) over the course of the experiment (p < 0.05) as 
assessed by ANOVA, but no differences were found in their expression at any of the 
individual time points. There was no effect on the expression of ADAMTS1, CD14, 
CXCL14, DEFB4 or S100A8 (Figure 5.6) over the course of the experiment or at any 
individual time point. 
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Figure 5.3 – The addition of IL-6 (100ng/ml) had no significant effect on the expression of 
any of the 5 inflammatory cytokines IL-1β, IL-6, IL-8, TNF-α or IFN-γ. Data are presented 
as means ± SEM. 
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Figure 5.4 – The addition of IL-6 (100ng/ml) had no significant effect on the expression of 
any of the 7 laminitis-associated genes ADAMTS1, CCL2, CD14, CXCL14, DEFB4, SOD2 
and S100A8. Data are presented as means ± SEM. 
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Figure 5.5 – The addition of LPS (1µg/ml) significantly increased the expression of IL-1β (p 
< 0.001), IL-6 (p < 0.001), and IL-8 (p < 0.0001) at 4 h but had no effect on the expression of 
TNF-α or IFN-γ at any time points. Data are presented as means ± SEM. 
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Figure 5.6 – The addition of LPS (1µg/ml) significantly increased the expression of CCL2 
and SOD2 across the entire experiment (p < 0.05) but no differences were found at any 
individual time point. There were no significant differences in the expression of ADAMTS1, 
CD14, CXCL14, DEFB4 or S100A8 at any time point or over the course of the experiment. 
Data are presented as means ± SEM. 
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Cytokine correlations: To determine if the differences between horses in cytokine expression 
were robust, we looked at correlations between cytokine levels (Figure 5.7) at the 4 h time 
point, where significant differences between groups had been measured. In general, horse 2 
and horse 5 showed lower correlation between cytokine expression levels than the other 3 
animals. The cytokines that showed significant differences in expression at the 4 h time point 
in response to LPS (IL-1β, IL-6 and IL-8) were well correlated, with R2 values averaging 
from 0.815 to 0.931 across the 5 animals. Correlations involving TNF-α and IFN-γ had low 
average R2 values across the 5 animals, with none exceeding 0.711 (for TNF-α and IL-8), 
and 4 of the 7 relationships having R2 values of below 0.4 (Table 5.1).  
 
Inter-animal variation: Cytokine values were compared between horses in the LPS treatment 
group at the 4 h time point, the only time point where significant differences from the control 
were seen (Figure 5.8). Horses tended to be either high responders (horses 1, 3, and 4) or low 
responders (horses 2 and 5). In particular, horse 5 had lower expression levels than the 
average for all cytokines (Table 5.2), and the lowest expression of cytokines measured to be 
significantly different in response to LPS treatment (IL-1β, IL-6, and IL-8). Because horse 5 
had consistently lower cytokine expression levels than the other animals in addition to 
relatively low cytokine correlations, we re-analyzed the data after the omission of horse 5. 
Removal of this animal, however, did not change the conclusions of our analysis. 
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Figure 5.7 – Correlations between inflammatory cytokine expression levels at the 4 h time 
point in each of the 5 horses.  
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Figure 5.7 (continued) 
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Table 5.1 – R2 values for correlations between inflammatory cytokine expression levels in all 
samples in each of the 5 horses. 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine R
2 Value 
Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Average 
IL-1β/IL-6 0.952 0.625 0.991 0.974 0.531 0.815 
IL-1β/IL-8 0.999 0.721 0.989 0.981 0.964 0.931 
IL-6/IL-8 0.935 0.798 0.994 0.998 0.655 0.876 
IL-6/TNF-α 0.899 0.798 0.212 0.854 0.655 0.683 
TNF-α/IL-1β 0.988 0.625 0.183 0.797 0.964 0.711 
TNF-α/IL-8 0.994 0.630 0.258 0.846 0.819 0.710 
TNF-α/IFN-γ 0.149 0.012 0.870 0.837 0.003 0.374 
IFN-γ/IL-1β 0.195 0.008 0.476 0.847 0.073 0.320 
IFN-γ/IL-6 0.325 0.045 0.509 0.851 0.072 0.360 
IFN-γ/IL-8 0.170 0.001 0.568 0.820 0.065 0.325 
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Figure 5.8 – Expression values of inflammatory cytokines in LPS treated samples after 4 h in 
each horse. 
 
 
 
 
 
 
 
Cytokine 
Expression Level 
Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Average 
IL-1β 15.88967 4.254074 18.67075 10.1872 2.253305 10.2509998 
IL-6 18.85686 9.854927 13.17479 15.46233 2.217667 11.9133148 
IL-8 12.13428 7.184288 14.1596 11.07846 1.462101 9.2037458 
IFN-γ 1.902659 1.162189 10.45201 5.432763 1.711241 4.1321724 
TNF-α 2.205364 2.234334 6.886201 2.150521 2.662982 3.2278804 
 
Table 5.2 – Expression values for inflammatory cytokines in LPS treated samples after 4 h.  
 
 
 
 
 
 
    41 
5.2 ApoA-IV 
APOA4 expression panel: APOA4 was detected in at least one animal in the small intestine, 
colon, cecum, liver, brain, stomach, tongue, lung, heart, spleen, adipose tissue, and eye by 
qualitative PCR (Figure 5.9). APOA4 could also be detected in the same tissues by real-time 
PCR with the highest expression in the liver (Figure 5.10). Neither technique identified 
APOA4 as expressed in the pancreas of either of the two animals for which this organ was 
sampled. When the liver was excluded from the tissue culture panel, the highest expression 
was noted in the small intestine. Small intestine expression was higher than liver expression 
in the horse with the lowest liver expression of APOA4. 
 
 
 
 
 
 
Figure 5.9 – Qualitative PCR results for tissue panel of APOA4 expression. 10µl PCR 
product was run on a 2% agarose gel.  
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Figure 5.10 – Real-time PCR results for tissue panel of APOA4 expression. Expression value 
are normalized to gamma actin, and compared to the average expression across all tissues in 
the culture. Circles show expression level for individual horses in each tissue. 
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Addition of recombinant apoA-IV to tissue culture: The addition of recombinant human 
apoA-IV (25µg/ml) alone to cultured laminar tissue did not result in a significant change in 
expression for any of the inflammatory cytokines (Figure 5.11) or laminitis associated genes 
(Figure 5.12) as assessed by ANOVA. Because the highest levels of inflammatory cytokines 
and laminitis associated gene expression occurred at the 4 h time point, we compared apoA-
IV treatment to the control group at the 4 h time point using a paired t-test, but found no 
significant differences. Although there appeared to be an increase in the expression of 
inflammatory cytokines and laminitis-associated genes (Figures 5.11 and 5.12), this was 
primarily due to a single animal (horse number 1). The addition of apoA-IV in combination 
with LPS (Figures 5.13 and 5.14) or with IL-6 (Figures 5.15 and 5.16) had no significant 
effect on gene expression. The results did not differ significantly from adding LPS or IL-6 
alone in either case. 
 
APOA4 expression in tissue culture: The expression of APOA4 was not significantly 
affected by the addition of LPS or IL-6, and was also unchanged by the addition of apoA-IV 
alongside LPS and IL-6 (Figure 5.17). However, expression of apoA-IV was very low in the 
laminar tissue, with an average Ct value of 35.86 (ranging from 29.69 to 40) and an average 
difference between replicates of 1.22, which likely contributed to the high standard error 
across samples for APOA4 expression. 
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Figure 5.11 – The addition of recombinant human apoA-IV (25µg/ml) did not significantly 
affect the expression of inflammatory cytokines IL-1β, IL-6, IL-8, TNF-α or IFN-γ. Data are 
presented as means ± SEM. 
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Figure 5.12 – The addition of recombinant human apoA-IV (25µg/ml) did not significantly 
affect the expression of laminitis-associated genes ADAMTS1, CCL2, CD14, CXCL14, 
DEFB4, S100A8 and SOD2. Data are presented as means ± SEM. 
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Figure 5.13 – The addition of recombinant human apoA-IV (25µg/ml) with LPS had no 
significant effect on the expression of the inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α 
and IFN-γ) when compared to the LPS treatment. Data are presented as means ± SEM. 
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Figure 5.14 – The addition of recombinant human apoA-IV (25µg/ml) with LPS had no 
significant effect on the expression of the laminitis-associated genes (ADAMTS1, CCL2, 
CD14, CXCL14, DEFB4, S100A8 and SOD2) when compared with the LPS treatment. Data 
are presented as means ± SEM. 
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Figure 5.15 – The addition of recombinant human apoA-IV (25µg/ml) with IL-6 had no 
significant effect on the expression of the inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α 
and IFN-γ) when compared to the IL-6 treatment. Data are presented as means ± SEM. 
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Figure 5.16 – The addition of recombinant human apoA-IV (25µg/ml) with IL-6 had no 
significant effect on the expression of the laminitis-associated genes (ADAMTS1, CCL2, 
CD14, CXCL14, DEFB4, S100A8 and SOD2) when compared with the IL-6 treatment. Data 
are presented as means ± SEM. 
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Figure 5.17 – The addition of IL-6 (A) or LPS (B) did not significantly affect the expression 
of APOA4. The addition of apoA-IV with LPS (C) or IL-6 (D) did not affect the expression 
of APOA4. Data are presented as means ± SEM. 
 
    51 
ApoA-IV isolation: A western blot with 1µl plasma in each lane using monoclonal anti-
human apoA-IV as a primary antibody and HRP-conjugated goat anti-mouse IgG as 
secondary antibody identified a protein around 28 kDa (Figure 5.18). The same band was 
visible when 10µg of laminar tissue proteins were run under the same conditions (Figure 
5.18). Previous attempts to identify apoA-IV by mass spec from this band on a 1D gel were 
unsuccessful (unpublished data). Laminar tissue proteins separated by 2D gel electrophoresis 
showed different patterns of signal using the monoclonal anti-apoA-IV antibody (Figure 
5.19) and a polyclonal anti-apoA-IV antibody (Figure 5.20). Spots with the strongest signal 
in each gel that were around the previously reported 28 kDa mark and the predicted 43 kDa 
size of the protein were cut out from a GelCode Blue Safe Protein Stain stained gel run under 
the same conditions (Figure 5.21). None of these 6 spots contained measurable levels of 
apoA-IV as determined by mass-spec analysis.  
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                           A. 
 
 
 
                            B. 
 
 
Figure 5.18 – Western blots with monoclonal anti-human apoA-IV primary antibody 
(Abcam, Cambridge, UK) and HRP-conjugated goat anti-mouse secondary antibody (Abcam, 
Cambridge, UK). A: equine plasma (1µl/lane) B: equine laminar tissue proteins (10µg/lane).  
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Figure 5.19 – Western blot from a 2D gel loaded with 70 µg of laminar tissue protein with 
monoclonal anti-human apoA-IV primary antibody (Abcam, Cambridge, UK) and HRP-
conjugated goat anti-mouse secondary antibody (Abcam, Cambridge, UK). Blue circles 
indicate spots that were selected for mass spec analysis. 
 
 
 
 
Figure 5.20 – Western blot from a 2D gel loaded with 70 µg of laminar tissue protein with 
polyclonal anti-human apoA-IV primary antibody (Abcam, Cambridge, UK) and HRP-
conjugated goat anti-rabbit secondary antibody (Abcam, Cambridge, UK). Yellow circles 
indicate spots that were selected for mass spec analysis. 
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Figure 5.21 – A 2D gel loaded with 70 µg of laminar tissue protein stained with GelCode 
Blue Safe Protein Stain (Thermo Fisher Scientific Inc., Rockford, IL). Spots from polyclonal 
antibody western blot are marked in yellow and spots from monoclonal antibody western blot 
are marked in blue.  
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 Product from an immunoprecipitation using the monoclonal anti-human apoA-IV 
antibody in equine plasma run on a 4-12% polyacrylamide gel showed one band which was 
not present in the mouse serum control in both reducing and non-reducing conditions (Figure 
5.22). However, it was shown that this band also appeared when the anti-apoA-IV antibody 
used in the immunoprecipitation was run on a gel as a control, showing that it was most 
likely a relic of that specific antibody and not its bound product (Figure 5.23). The 
immunoprecipitation western blots (Figure 5.22) also show a shift of the band in the plasma 
sample from around 28 kDa in the reducing gel to above the 98 kDa marker in the non-
reducing gel. Given that these sizes roughly correspond to the size of IgG light chain alone 
and an intact IgG antibody, a western blot was conducted on equine plasma 1µl/lane with 
only the goat anti-mouse IgG secondary antibody to test for cross-reaction. This showed that 
the band seen in our initial western blot was due to cross-reaction with the secondary 
antibody (Figure 5.24). A western blot was run with 5µg of affinity purified equine IgG and 
only the HRP-conjugated goat anti-mouse secondary antibody showed some cross-reaction 
with the secondary antibody (Figure 5.25).  
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A.                                                                             B. 
 
 
Figure 5.22 – Western blots of IP product run under reducing conditions (A) and non-
reducing conditions (B) using monoclonal anti-human apoA-IV primary antibody (Abcam, 
Cambridge, UK) and HRP-conjugated goat anti-mouse IgG secondary antibody (Abcam, 
Cambridge, UK). Each IP product lane contains 100µl of precipitated and lyophilized 
immunoprecipitation elution re-dissolved in loading buffer. Lanes contain A: 
immunoprecipitation with anti-human apoA-IV monoclonal antibody, B: 
immunoprecipitation with mouse serum control, and P: equine plasma (1µl/lane). Arrows 
indicate band present only in immunoprecipitation with antibody and not present in the 
serum control. 
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Figure 5.23 – Western blot with immunoprecipitation product from monoclonal anti-human 
apoA-IV antibody (IPA), 1µl plasma (P), and 5ul of monoclonal anti-human ApoA-IV 
antibody (mAb). Blot was run using monoclonal anti-human apoA-IV primary antibody 
(Abcam, Cambridge, UK) and HRP-conjugated goat anti-mouse IgG secondary antibody 
(Abcam, Cambridge, UK). Arrows indicate band that was present only in 
immunoprecipitation with antibody and not serum control. 
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Figure 5.24 – Western blot of equine plasma (1µl/lane) with only goat anti-mouse secondary 
antibody (Abcam, Cambridge, UK) and no primary antibody. 
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Figure 5.25 – Western blot of affinity purified equine IgG (5µg) using monoclonal anti-
human apoA-IV primary antibody (Abcam, Cambridge, UK) and HRP-conjugated goat anti-
mouse IgG secondary antibody (Abcam, Cambridge, UK). 
 
 
Several other anti-IgG antibodies were tested, but all were found to cross-react 
(Figure 5.26). Running a western blot with only the secondary antibody HRP-conjugated 
goat anti-rabbit (Abcam) resulted in a number of cross-reacting bands. When a western blot 
was run on the immunoprecipitation product from monoclonal anti-human apoA-IV (Abcam) 
using the same primary antibody as that from the immunoprecipitation and HRP-conjugated 
anti-mouse IgG VeriBlot antibody (Abcam), which is designed to bind only to intact 
antibody, as a secondary antibody, cross-reaction still occurred under reducing conditions. 
HRP-conjugated monoclonal anti-human apoA-IV had high background because the HRP-
conjugation was conducted in an antibody in ascites fluid, but no bands were seen around the 
predicted size for apoA-IV. Because these results provide no evidence that apoA-IV is found 
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at 28 kDa and not the expected 43 kDa on a western blot, no further attempts were made to 
isolate and sequence the protein. 
 
 
 
 A.                         B.                                        C.   
 
 
Figure 5.26 – Western blots for apoA-IV using alternative secondary antibodies. A: western 
blot with 1µl plasma using no primary antibody and HRP-conjugated polyclonal goat-anti 
rabbit IgG (Abcam, Cambridge, UK) as a secondary antibody. B: western blot with 
immunoprecipitation product from monoclonal anti-human apoA-IV antibody (IPA) and 
mouse serum control (IPS) using monoclonal anti-human apoA-IV antibody as a primary 
antibody and HRP-conjugated anti-mouse IgG VeriBlot antibody (Abcam, Cambridge, UK) 
as a secondary antibody. C: western blot with 1µl plasma (P), 1µl depleted plasma (DP), 
immunoprecipitation product from monoclonal anti-human apoA-IV antibody (IPA) and 
mouse serum control (IPS) using HRP-conjugated monoclonal anti-human apoA-IV as the 
single antibody.  
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6. CONCLUSION 
  
6.1 Background 
 Laminitis is a common equine disease in which inflammation occurs in the laminar 
tissue, which connects the hoof wall to the distal phalanx. Laminitis has broad impacts in the 
equine industry, having been estimated by one study to affect 15% of horses at some point in 
their lives [4], and to cost the industry around 13 million dollars annually [3] in medical 
expenses and the loss of animals that require euthanasia. The mechanisms behind the 
inflammation and damage to the laminar tissue during laminitis are not well understood, but 
two main underlying mechanisms have been suggested in the initiation of the disease: 
ishchaemia followed by reperfusion into the hoof tissue [2, 44, 76], and the action of an 
inflammatory agent initiating an inflammatory response in the animal [2, 76]. There has been 
debate in the literature as to which of these is responsible for causing the laminar tissue 
degradation seen in laminitis, but both processes are clearly important in laminitis [2, 76], 
regardless of which is ultimately responsible for initiating the disease process.  
 Acute laminitis is accompanied by a characteristic bounding digital pulse at the fetlock 
[2], indicative of vasoconstriction of vessels within the hoof, and reperfusion injuries have 
been seen in horses affected with the disease [44]. Increases in the production of 
inflammatory cytokines have been measured in a number of in-vivo acute laminitis studies 
across the carbohydrate overload [37, 51], black-walnut [49, 50, 52], hyperinsulinemia [53], 
and oligofructose-overload [38] models of laminitis within the first two days after treatment. 
These relatively early measurements of increases in inflammatory cytokines indicate that 
laminar tissue inflammation occurs in the initial stages of the disease. IL-6 has been observed 
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to be increased in the laminar tissue as early as 12 hours post-induction in the oligofructose 
overload model of the disease [38]. Although these changes in inflammatory signaling have 
been observed in a number of studies, the mechanisms underlying this shift to an 
inflammatory state remain unclear. Suggestions for inflammatory mediators include D-lactate 
[77] and LPS [24, 25] produced in the gut due to a shift in microbial populations, and the 
early involvement of the inflammatory cytokine interleukin 6 (IL-6) in the development of 
the disease [38]. Identifying the causative agent(s) in the development of laminar tissue 
inflammation is an important step in the understanding of the disease and the eventual 
development of effective treatment strategies, which are currently extremely limited. 
 
6.2 Tissue culture model 
 The vast majority of laminitis research today relies on the induction of the disease in 
live animals. In addition to the large number of animals that must be sacrificed for this type 
of research, sample groups are typically small and variable in age and health. Here we 
present a tissue culture model for the disease in which laminar tissue from horses euthanized 
for reasons unrelated to hoof lameness can be treated with an inflammatory agent to mimic 
the inflammation found in the laminar tissue during laminitis. This model allows for treated 
samples to be compared back to untreated control samples from the same animal at each time 
point, thus reducing the amount of variation introduced due to a heterogeneous sample 
population. In our model we use Leibovitz’s medium because it has been shown previously 
to maintain tissue morphology in culture [78, 79], and is a minimal medium that better 
reflects the non-proliferative in vivo state of the laminar tissue. Because this model allows 
for the direct addition of potential causative agents to the laminar tissue, it allows for the 
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determination their effects on this particular tissue, eliminating down-stream effects from the 
agent’s interaction with other organ systems. While in-vivo studies are important in 
providing a picture of the course of the disease over time and a system-wide view of the 
animal, isolating the laminar tissue is an important step in determining the mechanisms that 
drive inflammation in this specific tissue. 
 We were successful in keeping laminar tissue viable throughout the slices over the 
course of the experiment as determined by MTT staining. Nearly all samples remained free 
of contamination over the course of the experiment, with only two samples being discarded. 
These results show that our setup is a viable option for laminar tissue culture, and that 
experiments can be carried out over multiple days in this model. This would allow our model 
to be used in studies in which several elements were introduced over time; for example, 
inflammation could be initiated in the tissue prior to adding a potential anti-inflammatory 
intervention to test possible drugs and treatments in vitro before moving to live animal 
models. Inflammatory cytokine expression was increased in the controls over the course of 
the experiment, likely due to mechanical damage to the tissue during collection. However, as 
the highest effect was seen at 4 h, it is unlikely that there was a significant difference in 
inflammatory cytokine protein production after this short a period of time that would affect 
the tissue culture. Additionally, as we compared treatments to controls for each time point, 
this culture-effect was accounted for in our analysis. 
 In the future, this model could also be of use in testing the effects of agents suspected 
of having a causal role in laminitis on laminar tissue in vitro. Because the laminar tissue is 
isolated, this model distinguishes between agents that affect the laminar tissue directly to 
induce inflammation and those that act in other organs of the horse to produce upstream 
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effects that eventually result in laminar tissue inflammation. This distinction is important 
because it could help to determine the sequence of events in the development of the disease 
and provide information as to the level at which potentially causative agents act in the horse.  
 One current limitation of the model is that it does not simulate the load bearing stress 
normally exerted on the laminar tissue in a live animal. Given the constant force laminar 
tissue in live animals is under and the role of load-bearing stress in the development of 
laminitis [14, 70, 80], future development of the model could include culturing the tissue 
under conditions of shear force to mimic the mechanical stress exerted on the tissue in vivo. 
Additionally, it could be useful to further characterize the model histologically in order to 
determine whether cellular organization remains intact over the course of the experiment in 
the control treatment and if the histological changes induced in live animals with laminitis 
can be seen in the treated tissue in our model.  
 
6.3 Effects of LPS and IL-6 on laminar tissue inflammation 
 We tested two different inflammatory agents, lipopolysaccharide (LPS) and interleukin 
6 (IL-6), to compare their effects on gene expression on the laminar tissue in our model to 
changes in gene expression measured in animals experiencing laminitis. These agents were 
chosen based on their previous associations with laminitis, and gene expression was 
measured in genes that had been shown to change consistently across models of laminitis. 
We found that the addition of LPS was more successful in inducing gene expression patterns 
mimicking those found in vivo in animals experiencing laminitis than was the addition of IL-
6.  
 LPS is an important structural component in the cell wall of gram-negative bacteria 
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used by the immune system to identify a bacterial infection. LPS is recognized by toll-like 
receptor 4 (TLR4), which initiates a signaling pathway leading to the activation of 
inflammation-related genes [81-83]. In order for the immune system to detect an intrusion of 
gram-negative bacteria, LPS is initially disassociated from the outer membrane of these 
bacteria by LPS binding protein (LBP) [84]. Aggregates of dissociated LPS are then bound to 
CD14, a membrane-bound co-receptor which splits these aggregates into LPS monomers that 
can more easily bind to toll-like receptor 4 [84]. TLR4 acts in conjunction with a protein 
called MD-2 to form a complex that binds more readily to LPS than TLR4 alone [84-86]. 
Once bound to LPS, the TLR4/MD-2 complex aggregates with other LPS-bound complexes 
to initiate a signaling cascade resulting in the activation of transcription factors including 
NFKB [84, 86]. Once NFKB has been activated, it is translocated into the nucleus where it 
functions to upregulate the production of inflammatory cytokines and other inflammation-
associated genes [84, 86]. LPS is also known to induce polyclonal activation of B-cells 
through TLR4 [83, 87], but the expression of B-cell specific transcripts have been shown to 
decrease in horses with induced laminitis [88] and plasma levels of immunoglobulin were 
unaltered in horses with chronic laminitis [72]. In our study LPS was added alone without the 
addition of LBP (normally found in the plasma). Although this may have affected the 
strength of the signaling reaction to LPS, measurable responses in gene expression were still 
obtained. It was not possible to add equine plasma to our culture as this results in the 
proliferation of cells in the laminar tissue, an activity that does not occur in vivo and could 
alter the structure of the laminar tissue. 
 There is reason to believe that LPS may be involved at some level in the development 
of laminitis. It has been suggested that a shift in gut bacteria in carbohydrate overload and 
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pasture associated laminitis leads to an increase in LPS in the gut which is responsible for 
inducing the inflammation in the laminar tissue seen in laminitis [24]. LPS has been shown to 
be increased in oligofructose-induced laminitis [24] and in cecal fluid following carbohydrate 
overload [89].  Additionally, anti-LPS immunoglobulin has been measured to increase 
following colic [25], a condition that often precedes laminitis. Anti-LPS has also been 
measured in the plasma of humans with rheumatoid arthritis [90, 91] and been associated 
with lower mortality following traumatic injury [92] and reducing endotoxemia [93]. 
However, despite the correlation between increased LPS levels and gastrointestinal disorders 
and laminitis, intravenous administration of LPS alone is not sufficient to induce laminitis in 
live animals [76, 94]. Additionally, while there are increases in specific gram-negative 
species in the gut during laminitis, the overall shift in bacteria has been shown to be towards 
an increase in gram-positive species [19-21]. This indicates that, while LPS may play a role 
in laminar tissue inflammation in horses with laminitis, it is not the only factor involved in 
the initiation and development of the disease. Despite previous research indicating that the 
production of LPS may be involved in the development of laminitis, its role (if any) in 
laminitis is not understood, and the effects of LPS on laminar tissue are unknown. 
 In this study, the addition of LPS to cultured laminar tissue caused the expression of 
inflammatory cytokines to change after 4 h to mimic the pattern seen in horses experiencing 
acute laminitis. As in most animal studies, IL-1β, IL-6, and IL-8 were increased at this time 
point while TNF-α and IFN-γ remained unchanged. In live animal studies IL-1β [49-52], IL-
6 [38, 49-51], and IL-8 [49, 50] were also measured to increase in expression across multiple 
models. As seen in our tissue culture experiment, the expression of TNF-α [50, 51] has been 
shown to remain unchanged in the laminar tissue during induced laminitis. IFN-γ has also 
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been shown to remain unchanged in the black walnut [49] and carbohydrate overload [51] 
models of laminitis, although it was shown to increase in the oligofructose overload model of 
the disease [49]. The high correlation between the expression levels of cytokines measured to 
be significantly affected by LPS (IL-1β, IL-6, and IL-8) provides evidence that our 
measurement were robust and indicative of an underlying biological response. Additionally, 
correlations involving the cytokines that were not significantly affected (TNF-α and IFN-γ) 
were much lower, further indicating that the expression of these genes was probably not 
responding in a clear pattern to the addition of LPS. 
 The observed increases in IL-1β, IL-6, and IL-8 can be explained by the action of the 
transcription factor NFKB (Figure 6.1), which is relocated into the nucleus following TLR4 
activation by LPS. NFKB is known to have a functional binding site for IL-1β [95] and to 
regulate the expression of IL-6 [96, 97] and IL-8 [98, 99].  However, NFKB has also been 
implicated in the transcriptional regulation of TNF-α [100, 101] and IFN-γ [102, 103], which 
were not significantly changed at any time point in this experiment. Further research on the 
factors regulating inflammatory cytokine production during laminitis may shed light on why 
the pro-inflammatory cytokines TNF-α and IFN-γ were not upregulated in the disease or in 
our model.  
 Increases in IL-1β, IL-6, and IL-8 expression in the laminar tissue during laminitis 
could play an important role in the recruitment of leukocytes into the tissue. IL-1β is known 
to act in recruiting neutrophils [104, 105], which have been shown to be increased in the 
laminar tissues in horses with laminitis [7, 38, 72, 106]. This increase in neutrophils is 
associated with increased levels of metalloproteinases [29, 30], which may contribute to 
tissue damage in the laminar tissue during laminitis. In addition, IL-1β is involved in 
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collagen production [104], of note because collagen is one of the major components of the 
basement membrane that is degraded during laminitis, and blocking the production of IFN-γ 
[104, 107], which could explain the lack of response in this particular cytokine during 
laminitis. IL-6 plays an important role in initiating an immune response. It has been shown to 
be involved in the recruitment of leukocytes [108] and has been suggested to play such a role 
in laminitis [38]. Additionally, IL-8 is well known to play a role in the recruitment of 
neutrophils [109, 110]. Taken together, increased expression of these cytokines indicates an 
inflammatory response in the laminar tissue, recruiting leukocytes (especially neutrophils) 
into the tissue and ramping up the local immune response. 
 In addition to the increased expression of several inflammatory cytokines, two of the 
seven laminitis-associated genes we measured (CCL2 and SOD2) were increased over the 
course of the experiment, although differences were not significant at any specific time point. 
CCL2 and superoxide dismutase (SOD) were increased in the laminar tissue of horses with 
black walnut extract induced laminitis [88], showing CCL2 and a superoxide dismutase 
enzyme to be affected in multiple live-animal studies. CCL2 is known to recruit monocytes 
and macrophages and to be released in response to oxidative stress [111]. SOD2 functions to 
transform superoxide (which is toxic to cells) into hydrogen peroxide and diatomic oxygen 
and is known to be produced by neutrophils [112, 113]. The increased expression of SOD2 in 
the laminar tissue in horses with laminitis [71] could be a response to mitigate the damaging 
effects of oxidative stress introduced by neutrophils on the laminar tissue.  
 The expression pattern of the laminitis-associated genes can also be explained through 
the activation of NFKB (Figure 6.1). CCL2 [114-116] and SOD2 [117, 118] are also both 
target genes of NFKB while the other, unaffected, laminitis-associated genes have not been 
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identified in the literature as targets for this transcription factor. Although our results show 
that LPS exposure is not a perfect model for laminitis, the cytokine expression profile 
resulting from LPS treatment may produce a viable model for certain future studies, 
particularly those that are expected to act through the NFKB pathway. 
 
 
Figure 6.1 – Gene expression regulation through TLR4. LPS signaling through the TLR4 
receptor activates NFKB which is translocated to the nucleus where it can upregulate the 
expression of the inflammatory cytokines and laminitis associated genes measured to 
increase in this study in addition to many other inflammation-related genes.  
 
  
 Application of the second inflammatory agent used in this study, IL-6, did not produce 
changes in gene expression in the laminar tissue culture consistent with those found in the 
laminar tissue of horses experiencing laminitis. IL-6 is an inflammatory cytokine involved in 
a wide number of biological processes including inflammation, oncogenesis, hematopoiesis, 
and immune regulation [119]. The protein functions by binding to the IL-6 receptor (IL-6R) 
which leads to the homodimerization of gp130, a cell surface protein that serves as a signal 
transducer for a number of cytokines including IL-6 [119-122]. The binding of IL-6 to the 
IL-6R and subsequent homodimerization of gp130 leads to the activation of JAKs which then 
    70 
activates STAT1 and STAT3. After activation these proteins are able to form homodimers or 
heterodimers that, when transported to the nucleus, induce transcription of target genes [119, 
122-125]. 
  IL-6 production has been implicated in the development of laminitis [38] and has was 
increased in the black walnut [49, 50], oligofructose [38], and carbohydrate overload [51] 
models of the disease. IL-6 was shown to induce changes in matrix metalloproteinase 
expression in vitro in a previous study [38]. In this case recombinant equine IL-6 was added 
to laminar tissue explants 5mm x 5mm at varying concentrations. At a concentration of 
100ng/ml and 500ng/ml, IL-6 was seen to increase the expression of pro MMP-9 although 
the changes were lost at a concentration of 1000ng/ml, and no changes were observed in the 
concentration of pro MMP-2 at any concentration of IL-6. The authors suggest that IL-6 may 
act in the recruitment of leukocytes into the laminar tissue, and that it may do so through an 
increase in the production of MMP-9. However, the role of IL-6 in laminar tissue 
inflammation is currently not understood, and in this study we examined its effects on 
laminar tissue in isolation to determine if the protein alone had the ability to induce 
inflammation in cultured laminar tissue. 
 We found that the addition of IL-6 by itself was not sufficient to significantly affect 
the expression of any of the measured inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α, or 
IFN-γ). IL-6 also did not affect the expression of the laminitis-associated genes ADAMTS1, 
CCL2, CD14, CXCL14, DEFB4, S100A8, or SOD2. Our results suggest that IL-6 alone is 
not sufficient in driving laminar tissue inflammation. However, this protein could still be 
important in the development of laminitis through the recruitment of leukocytes, as 
previously postulated [38]. Our results support the idea that the role of IL-6 in laminitis is 
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related to the involvement of factors not normally found in the laminar tissue as If IL-6-
mediated recruitment of leukocytes or other factors into the laminar tissue would not be 
reflected in our model. Additionally, the large inter-animal variation in our study may have 
contributed to these results due to the high standard error in our measurements and future 
studies with larger numbers of animals may yield less variable results. 
 This variation could also be indicative of physiological differences between animals 
in susceptibility to developing laminar tissue inflammation. In several previous in-vivo 
laminitis studies, a minority of horses were considered “non-responders” as they never 
developed the disease despite undergoing the same treatment as affected animals [6, 20, 36, 
51, 126]. In our experiment, we observed variation in the magnitude of the response to the 
addition of LPS and IL-6. At 4 h, when the maximal effect was measured, horse number five 
expressed notably lower levels of inflammatory cytokines in response to both LPS and IL-6 
than the other animals. Additionally, this animal showed lower levels of correlation between 
the expression of different inflammatory cytokines. This raises the possibility that some 
horses in our model may not respond to inflammatory agents in their laminar tissue to the 
same degree as the majority, possibly mimicking the “non-responders” found in in vivo 
trials. Although further studies would be needed to confirm the presence of non-responders in 
our tissue model, given the relatively small number of animals in our trial and variation in 
age, breed, and sex, these animals could prove useful in understanding how inflammation is 
initiated in the laminar tissue and why some animals are naturally more susceptible or 
resistant to the development of laminitis than others. 
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6.4 Role of apoA-IV in laminar tissue inflammation 
Apolipoproteins are proteins associated with lipoproteins, particles responsible for the 
transport of lipids through the body. Apolipoprotein A-IV (apoA-IV) is associated with high-
density lipoprotein, and, although its primary function is not established, it has been shown to 
be involved in a number of diverse processes including appetite regulation [63], anti-oxidant 
activity [127], amyloid B clearing [65], and anti-inflammatory activity [57]. In a previous 
study [56], apoA-IV was shown to be increased by over two-fold in the plasma of horses 
with chronic laminitis when compared to healthy controls. The protein has also been 
associated with two chronic inflammatory diseases in humans, ankylosing spondylitis [68], 
and rheumatoid arthritis [67]. Additionally, it has been shown to have an anti-inflammatory 
role in mitigating experimentally induced colitis in mice [57].  
Currently, the role of apoA-IV in laminitis is not known, but its association with 
chronic laminitis and human inflammatory diseases make apoA-IV an important protein to 
investigate further in the pathogenesis of laminitis. Thus, we conducted an in-vitro 
experiment to test the effect of apoA-IV on the expression of inflammatory cytokines and 
laminitis associated genes in laminar tissue alone and in the presence of two inflammatory 
agents. We also measured the response of APOA4 expression to the addition of the 
inflammatory mediators LPS and IL-6. Because very little is currently known about the 
production, distribution, and function of apoA-IV in the horse, we conducted a tissue panel 
and quantified expression levels of APOA4 at the RNA level to determine its distribution in 
the horse.  
To test the effects of apoA-IV on the laminar tissue under normal and inflamed 
conditions we added recombinant human apoA-IV to tissue with and without LPS and IL-6. 
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We found no effect of adding apoA-IV to laminar tissue under control conditions or in 
addition to either LPS or IL-6. There was no significant effect of apoA-IV treatment in any 
case on the expression of inflammatory cytokine genes or laminitis associated genes in the 
cultured laminar tissue. This indicates that apoA-IV is not responsible for directly 
modulating laminar tissue inflammation under normal or inflamed conditions. However, it 
remains possible that apoA-IV is an important mediator of laminitis, but acts through a 
mechanism not directly linked to the laminar tissue itself. Given the association between 
metabolic syndrome and laminitis, it is interesting to note that apoA-IV has been suggested 
to play a role in reducing oxidative stress during metabolic syndrome [128]. It is also known 
to reduce the hepatic lipid burden during hepatic steatosis [129], a problem associated with 
metabolic syndrome, by promoting lipoprotein particle expansion. ApoA-IV is increased in 
the plasma following 24 hours of fasting in mice [130], raising the possibility that it may be 
increased in response to a calorie-restricted diet given to horses with metabolic syndrome. 
The function of apoA-IV in chronic inflammatory disease remains to be elucidated, and 
further studies in this area are merited to determine whether this protein has any effect on the 
inflammatory state in these individuals. 
The addition of either LPS or IL-6 to tissue culture had no effect on the expression of 
APOA4 at any time point. However, the expression levels were very low in the laminar 
tissue across all treatments and time points. This low expression may have contributed to the 
variability in expression between horses and high standard error. Given the low level of 
expression in the laminar tissue it is unlikely that apoA-IV is synthesized in substantial 
quantities in this tissue. More likely, the increase in apoA-IV seen in horses with chronic 
laminitis is due to an increase in apoA-IV production in the liver and/or small intestine that is 
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secreted into the plasma to account for the increased levels of plasma apoA-IV. If apoA-IV is 
important in modulating laminar tissue inflammation during laminitis, it is most likely that 
this protein is transported in the blood to the hoof where it is able to act on laminar tissue. 
 Our tissue panel results showed apoA-IV to be measurably expressed in all tissues 
examined except the pancreas. However, the gene is much more highly expressed in the liver 
than in any other tissue, although notable quantities are also expressed in the small intestine. 
The high relative expression levels in the liver are of interest because not all animals 
synthesize apoA-IV in the liver. In humans, synthesis of apoA-IV is restricted to the small 
intestine [63] and, while the protein is produced in both the liver and small intestine in rats, 
the synthesis is higher in the small intestine than the liver in these animals [131]. The much 
higher relative expression levels found in the liver than in the intestine in most of our animals 
indicates that horses may balance the synthesis of apoA-IV differently between these organs 
than other animals previously studied. Hepatic apoA-IV expression has been associated with 
increased lipoprotein particle size [129], response to fasting [130], and suppression of 
glucose production [132], providing a number of possibilities for its role in the liver in 
horses. Because of this result, further studies on apoA-IV at the protein level and on its 
synthesis in the liver and small intestine of the horse are merited. 
 ApoA-IV expression levels between organs was not uniform between the horses, 
however, with one animal showing much lower expression in the liver and higher expression 
in the small intestine than the other animals. In this case expression in the small intestine 
outweighed expression in the liver, showing that there is potential for great variation in 
production levels between these organs. It is worth noting that we did not have any 
information about the feeding schedule of the animals included in this study and that the 
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production of apoA-IV by the small intestine is known to increase after lipid feeding in rats 
[63, 133-136] and humans [62, 63]. However, the effects of feeding on apoA-IV synthesis in 
horses remains unknown. Given that the production of apoA-IV is heavily tied to feeding, it 
is possible that differences in feeding times between the animals used in this study 
contributed to the altered expression pattern seen in one individual. Further studies are 
needed to determine how apoA-IV synthesis is regulated in the horse, particularly given the 
potentially high contribution of the liver in this animal. 
Because of size discrepancies between the reported and predicted apoA-IV sequence 
in the horse, we attempted to isolate and sequence apoA-IV to detect any modifications from 
its predicted sequence. ApoA-IV has been previously reported to be around 30 kDa in the 
horse [56]. This is in contrast to the size of the protein in other animals (46 kDa in humans 
[59], 46 kDa in rats [58], and 44-45 kDa in dogs [59]) and the size predicted for the horse by 
ExPASy ProtParam [61] of 43.3 kDa based on the predicted equine apoA-IV protein 
sequence from the NCBI protein sequence database [60] (reference sequence: 
XP_001502503.1). To address this discrepancy and search for any post-transcriptional or 
post-translational modifications we attempted to isolate the protein.  
Our results provide no evidence that apoA-IV is smaller than the predicted sequence 
of 43.3 kDa. Attempts to isolate the protein using 2D electrophoresis or immunoprecipitation 
with anti-human apoA-IV antibodies were unsuccessful. Additionally it was shown that the 
antibodies used previously to measure apoA-IV expression were showing cross-reaction with 
a different protein, potentially equine IgG, and do not detect apoA-IV. Attempts to find a 
secondary antibody that would not cross-react with equine plasma were unsuccessful. We 
HRP-conjugated the original anti-human apoA-IV antibody, but were not able to identify 
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equine apoA-IV in a western blot with equine plasma using this antibody. This indicates that 
the anti-human apoA-IV antibody is not able to recognize equine apoA-IV due to differences 
between the human and equine proteins. 
ApoA-IV is still likely to be increased during equine laminitis as a previous study 
[56] identified it in a spot on a 2D DIGE gel shown that was more highly expressed in horses 
with chronic laminitis than in controls. However, in order to verify this result with ELISA, it 
would be necessary to produce antibodies specific for equine apoA-IV as commercially 
available anti-human apoA-IV antibodies were not able to bind the equine protein in our 
western blots. The lack of equine reagents commercially available was a limiting factor in 
this study, but future work with equine apoA-IV remains to be done. Further studies should 
be conducted to confirm the increased concentration of apoA-IV in the plasma of horses with 
laminitis. These studies would need to involve producing the equine protein in-vitro and 
raising antibodies against it that could be used to measure the plasma concentration of apoA-
IV in horses by ELISA. These initial studies verifying an increase in the plasma levels of 
apoA-IV in horses with laminitis would need to be completed before further studies 
examining the role of apoA-IV in laminitis could be justified. 
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